{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:51:09Z","timestamp":1789080669720,"version":"build-2803163510"},"reference-count":26,"publisher":"The Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic abnormality with a worldwide prevalence of 4% to 21%, depending on diagnostic criteria. The National Institutes of Health (NIH) is the largest single funding agency in the world; it invests nearly $30.0 billion annually in biomedical research.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Evidence Acquisition<\/jats:title>\n                  <jats:p>Using the NIH Research Portfolio Online Reporting tool, we searched for all grants awarded by the NIH for PCOS and three other disorders with similar degrees of morbidity and similar or lower mortality and prevalence [rheumatoid arthritis (RA), tuberculosis (TB), and systemic lupus erythematosus (SLE)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Evidence Synthesis<\/jats:title>\n                  <jats:p>We compared funding by the NIH for PCOS, RA, TB, and SLE research for the years 2006 to 2015, inclusive.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>PCOS, compared with RA, TB, and SLE, was relatively less funded (total mean 10-year funding was $215.12 million vs $454.39 million, $773.77 million, and $609.52 million, respectively). Funding for PCOS was largely provided by one NIH Institute\/Center (ICs) vs at least two ICs for SLE and RA; more individual Research Project Grants were awarded for RA, SLE, and TB than for PCOS, whereas PCOS funding was more likely to be through General Clinical Research Centers Program or Specialized Centers Program awards. Our data suggest that PCOS research may be underfunded considering its prevalence, economic burden, metabolic morbidity, and negative impact on quality of life. Greater education of NIH leaders, including those at the National Heart, Lung, and Blood Institute and National Institutes of Diabetes and Digestive and Kidney Diseases; other federal and state agency leads; elected leaders; and the general public by professional societies, the scientific community, and patient advocates regarding this disorder is needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2017-01415","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T18:05:33Z","timestamp":1505844333000},"page":"4421-4427","source":"Crossref","is-referenced-by-count":66,"title":["Perspectives on Polycystic Ovary Syndrome: Is Polycystic Ovary Syndrome Research Underfunded?"],"prefix":"10.1210","volume":"102","author":[{"given":"Soumia","family":"Brakta","sequence":"first","affiliation":[{"name":"Department of OB\/GYN, Medical College of Georgia, Augusta University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Lizneva","sequence":"additional","affiliation":[{"name":"Department of OB\/GYN, Medical College of Georgia, Augusta University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Mykhalchenko","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Bronx-Lebanon Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adonis","family":"Imam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Orange Park Medical"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walidah","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of OB\/GYN, Medical College of Georgia, Augusta University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Diamond","sequence":"additional","affiliation":[{"name":"Department of OB\/GYN, Medical College of Georgia, Augusta University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Azziz","sequence":"additional","affiliation":[{"name":"Department of OB\/GYN, Medical College of Georgia, Augusta University"},{"name":"Department of Health Policy, Management, and Behavior, School of Public Health, University at Albany, State University of New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"issue":"2","key":"2020071622213081500_B1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"issue":"1","key":"2020071622213081500_B2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva","year":"2016","journal-title":"Fertil Steril"},{"issue":"4","key":"2020071622213081500_B3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ando.2014.07.111","article-title":"Long term complications of polycystic ovary syndrome (PCOS)","volume":"75","author":"Peign\u00e9","year":"2014","journal-title":"Ann Endocrinol (Paris)"},{"issue":"5","key":"2020071622213081500_B4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/humupd\/dmv029","article-title":"Pregnancy complications in women with polycystic ovary syndrome","volume":"21","author":"Palomba","year":"2015","journal-title":"Hum Reprod Update"},{"issue":"8","key":"2020071622213081500_B5","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1210\/jc.2005-0628","article-title":"Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span","volume":"90","author":"Azziz","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071622213081500_B6","unstructured":"National Institutes of Health. Budget. Available at: https:\/\/www.nih.gov\/about-nih\/what-we-do\/budget. Accessed May 20, 2017."},{"key":"2020071622213081500_B7","unstructured":"US Department of Health and Human Services. HHS FY2015 budget in brief. Available at: http:\/\/www.hhs.gov\/about\/budget\/fy2015\/budget-in-brief\/nih\/index.html. Accessed May 20, 2017."},{"issue":"7","key":"2020071622213081500_B8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0895-4356(98)00035-3","article-title":"Mortality of women with polycystic ovary syndrome at long-term follow-up","volume":"51","author":"Pierpoint","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2020071622213081500_B9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01000.x","article-title":"Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study","volume":"52","author":"Wild","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2020071622213081500_B10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/03009740410005845","article-title":"Death rates and causes of death in patients with rheumatoid arthritis: a population-based study","volume":"33","author":"Sihvonen","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"2020071622213081500_B11","unstructured":"Centers for Disease Control and Prevention\n          . Arthritis: Disability and Limitation Statistics. Available at: https:\/\/www.cdc.gov\/arthritis\/data_statistics\/disabilities-limitations.htm. Accessed June 28, 2017."},{"issue":"8","key":"2020071622213081500_B12","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2020071622213081500_B13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"2020071622213081500_B14","first-page":"229","article-title":"Trends in tuberculosis - United States, 2013","volume":"63","author":"Alami","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2020071622213081500_B15","first-page":"52","article-title":"Factors associated with mortality in tuberculosis patients","volume":"18","author":"Alavi-Naini","year":"2013","journal-title":"J Res Med Sci"},{"key":"2020071622213081500_B16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ebiom.2015.12.016","article-title":"Research investments in global health: a systematic analysis of UK infectious disease research funding and global health metrics, 1997-2013","volume":"3","author":"Head","year":"2015","journal-title":"EBioMedicine"},{"issue":"3","key":"2020071622213081500_B17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/003335491012500307","article-title":"Trends in tuberculosis mortality in the United States, 1990-2006: a population-based case-control study","volume":"125","author":"Jung","year":"2010","journal-title":"Public Health Rep"},{"key":"2020071622213081500_B18","unstructured":"Institute of Medicine. Women\u2019s health research: progress, pitfalls, and promise. 2010. Available at: https:\/\/www.nap.edu\/read\/12908\/chapter\/1. Accessed May 20, 2017."},{"issue":"6","key":"2020071622213081500_B19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev"},{"issue":"11","key":"2020071622213081500_B20","doi-asserted-by":"crossref","first-page":"e13526","DOI":"10.1371\/journal.pone.0013526","article-title":"An analysis of preliminary and post-discussion priority scores for grant applications peer reviewed by the Center for Scientific Review at the NIH","volume":"5","author":"Martin","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"2020071622213081500_B21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/CIRCRESAHA.114.302656","article-title":"Percentile ranking and citation impact of a large cohort of NHLBI-funded cardiovascular R01 grants","volume":"114","author":"Danthi","year":"2014","journal-title":"Circ Res"},{"issue":"6","key":"2020071622213081500_B22","doi-asserted-by":"crossref","first-page":"e0155060","DOI":"10.1371\/journal.pone.0155060","article-title":"How criterion scores predict the overall impact score and funding outcomes for National Institutes of Health peer-reviewed applications","volume":"11","author":"Eblen","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"2020071622213081500_B23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1098214015582049","article-title":"NIH peer review: scored review criteria and overall impact","volume":"37","author":"Lindner","year":"2016","journal-title":"Am J Eval"},{"issue":"2","key":"2020071622213081500_B24","first-page":"604","article-title":"Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome","volume":"102","author":"Gibson-Helm","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071622213081500_B25","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.fertnstert.2017.04.011","article-title":"Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome","volume":"107","author":"Dokras","year":"2017","journal-title":"Fertil Steril"},{"key":"2020071622213081500_B26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/epirev\/mxt002","article-title":"Influence of macrosocial policies on women\u2019s health and gender inequalities in health","volume":"36","author":"Borrell","year":"2014","journal-title":"Epidemiol Rev"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/12\/4421\/22224592\/jc.2017-01415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/12\/4421\/22224592\/jc.2017-01415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T10:39:40Z","timestamp":1594982380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/102\/12\/4421\/4162023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2017-01415","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12,1]]},"published":{"date-parts":[[2017,9,19]]}}}